Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("PEMBROREAL" Study).
Cafaro A, Foca F, Nanni O, Chiumente M, Coppola M, Russi A, Svegliati E, Baldo P, Orzetti S, Enrico F, Foglio F, Pinnavaia D, Ladisa V, Lauria Pantano C, Lerose R, Nardulli P, Ferraiuolo S, Maiolino P, De Stasio I, Gradellini F, Gasbarro AR, Santeramo R, Carrucciu G, Provasi R, Cirino M, Cappelletto PC, Fonzi E, Pasqualini A, Vecchia S, Veraldi M, De Francesco AE, Crinò L, Delmonte A, Masini C. Cafaro A, et al. Among authors: nanni o. Cancers (Basel). 2024 May 8;16(10):1802. doi: 10.3390/cancers16101802. Cancers (Basel). 2024. PMID: 38791882 Free PMC article.
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.
Bongiovanni A, Liverani C, Foca F, Bergamo F, Leo S, Pusceddu S, Gelsomino F, Brizzi MP, Di Meglio G, Spada F, Tamberi S, Lolli I, Cives M, Marconcini R, Pucci F, Berardi R, Antonuzzo L, Badalamenti G, Santini D, Recine F, Vanni S, Tebaldi M, Severi S, Rudnas B, Nanni O, Ranallo N, Crudi L, Calabrò L, Ibrahim T. Bongiovanni A, et al. Among authors: nanni o. Eur J Cancer. 2024 Sep;208:114129. doi: 10.1016/j.ejca.2024.114129. Epub 2024 May 25. Eur J Cancer. 2024. PMID: 39002347 Free article. Clinical Trial.
Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study.
Provinciali N, Piccininno M, Siri G, Gennari A, Antonucci G, Ricci D, Devoto E, Miceli R, Cortesi P, Pazzi C, Nanni O, Mannozzi F, Pastina I, Messuti L, Bengala C, Frassineti GL, Cattrini C, Fava M, Buttiron Webber T, Briata IM, Corradengo D, DeCensi A, Puntoni M. Provinciali N, et al. Among authors: nanni o. Rev Cardiovasc Med. 2024 Jul 9;25(7):256. doi: 10.31083/j.rcm2507256. eCollection 2024 Jul. Rev Cardiovasc Med. 2024. PMID: 39139415 Free PMC article.
A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL).
Cafaro A, Foca F, Nanni O, Chiumente M, Coppola M, Baldo P, Orzetti S, Enrico F, Ladisa V, Lerose R, Nardulli P, Maiolino P, Gradellini F, Gasbarro AR, Carrucciu G, Provasi R, Cappelletto PC, Pasqualini A, Vecchia S, Veraldi M, De Francesco AE, Crinò L, Delmonte A, Masini C. Cafaro A, et al. Among authors: nanni o. Front Oncol. 2024 Mar 27;14:1351995. doi: 10.3389/fonc.2024.1351995. eCollection 2024. Front Oncol. 2024. PMID: 38601759 Free PMC article.
Radiotherapy at the End of Life: From Retrospective Analysis to Strategies to Improve Outcomes.
Rossi R, Cravero P, Pallotti MC, Valenti V, Massa I, Foca F, Nanni O, Pieri M, Romeo A, Tontini L, Donati CM, Morganti AG, Maltoni M. Rossi R, et al. Among authors: nanni o. J Pain Symptom Manage. 2024 Jun;67(6):e927-e929. doi: 10.1016/j.jpainsymman.2024.03.001. Epub 2024 Mar 10. J Pain Symptom Manage. 2024. PMID: 38467347 No abstract available.
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.
Gennari A, Brain E, De Censi A, Nanni O, Wuerstlein R, Frassoldati A, Cortes J, Rossi V, Palleschi M, Alberini JL, Matteucci F, Piccardo A, Sacchetti G, Ilhan H, D'Avanzo F, Ruffilli B, Nardin S, Monti M, Puntoni M, Fontana V, Boni L, Harbeck N; ET-FES Collaborative Group. Gennari A, et al. Among authors: nanni o. Ann Oncol. 2024 Jun;35(6):549-558. doi: 10.1016/j.annonc.2024.02.007. Epub 2024 Feb 28. Ann Oncol. 2024. PMID: 38423389 Clinical Trial.
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.
Schettini F, Palleschi M, Mannozzi F, Brasó-Maristany F, Cecconetto L, Galván P, Mariotti M, Ferrari A, Scarpi E, Miserocchi A, Nanni O, Sanfeliu E, Prat A, Rocca A, De Giorgi U. Schettini F, et al. Among authors: nanni o. Oncologist. 2024 May 3;29(5):e622-e634. doi: 10.1093/oncolo/oyad337. Oncologist. 2024. PMID: 38175669 Free PMC article. Clinical Trial.
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial.
Grassi E, Zingaretti C, Petracci E, Corbelli J, Papiani G, Banchelli I, Valli I, Frassineti GL, Passardi A, Di Bartolomeo M, Pietrantonio F, Gelsomino F, Carandina I, Banzi M, Martella L, Bonetti AV, Boccaccino A, Molinari C, Marisi G, Ugolini G, Nanni O, Tamberi S. Grassi E, et al. Among authors: nanni o. ESMO Open. 2023 Oct;8(5):101824. doi: 10.1016/j.esmoop.2023.101824. Epub 2023 Sep 27. ESMO Open. 2023. PMID: 37774508 Free PMC article. Clinical Trial.
209 results